ADMA Biologics, Inc. vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored

Biotech Giants' Cost Efficiency: ADMA vs. CRISPR

__timestamp	ADMA Biologics, Inc.	CRISPR Therapeutics AG
Wednesday, January 1, 2014	3742367	1513000
Thursday, January 1, 2015	4311461	12573000
Friday, January 1, 2016	6360761	42238000
Sunday, January 1, 2017	29164321	69800000
Monday, January 1, 2018	42194635	113773000
Tuesday, January 1, 2019	39504238	179362000
Wednesday, January 1, 2020	61291426	269407000
Friday, January 1, 2021	79769341	17953000
Saturday, January 1, 2022	118814535	110250000
Sunday, January 1, 2023	169273000	130250000
Monday, January 1, 2024		-2314000

Data in motion

Exploring Cost Efficiency in Biotech: ADMA Biologics vs. CRISPR Therapeutics

In the dynamic world of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for ADMA Biologics, Inc. and CRISPR Therapeutics AG from 2014 to 2023. Over this period, ADMA Biologics demonstrated a significant increase in cost efficiency, with their cost of revenue growing by approximately 4,400%, from $3.7 million in 2014 to $169 million in 2023. In contrast, CRISPR Therapeutics saw a more moderate increase of around 8,500%, starting at $1.5 million in 2014 and reaching $130 million in 2023. Notably, CRISPR's cost of revenue peaked in 2020, highlighting a strategic shift or operational change. This comparison underscores the varying strategies and market conditions influencing these biotech giants, offering valuable insights for investors and industry analysts alike.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025